Genomics Bioscience & Technology Co

Genomics Bioscience & Technology Co Inventory

The Inventory of Genomics Bioscience & Technology Co (4195.TWO) as of Nov 12, 2026 is 235.82 M TWD. In the previous year, Inventory was 185.49 M TWD — a change of 27.13% (higher).

Inventory

235.82 MTWD

YoY

27.13%

Last updated:

Inventory of Genomics Bioscience & Technology Co is 2025 235.82 M TWD. Inventory of Genomics Bioscience & Technology Co was 2024 185.49 M TWD. It decreases by 27.13% higher compared to the previous year.

The Genomics Bioscience & Technology Co Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
21.99 M TWD
Jan 1, 2019
12.31 M TWD
Jan 1, 2020
24.00 M TWD
Jan 1, 2021
20.99 M TWD
Jan 1, 2022
54.80 M TWD
Jan 1, 2023
61.51 M TWD
Jan 1, 2024
185.49 M TWD
Jan 1, 2025
235.82 M TWD
The Genomics Bioscience & Technology Co Inventory history
YEARInventoryYoY
235.82 MTWD+27.13%
185.49 MTWD+201.57%
61.51 MTWD+12.25%
54.80 MTWD+161.05%
20.99 MTWD-12.53%
24.00 MTWD+95.01%
12.31 MTWD-44.03%
21.99 MTWD-61.55%
57.18 MTWD+0.03%
57.17 MTWD+5.81%
54.03 MTWD+25.03%
43.21 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomics Bioscience & Technology Co Stock analysis

What does Genomics Bioscience & Technology Co do? Genomics BioSci & Tech.Co., Ltd. generates revenue through the provision of public gene sequencing and clinical sequencing services, including preventive genetic testing, primer synthesis, and individualized medical and genetic screening for cancers. The company also manufactures and sells biochemical instruments, reagents, and consumables, distributing these products domestically and internationally. Its primary customers are healthcare providers and research institutions seeking genetic analysis and diagnostic solutions. The firm's services and products target both public health initiatives and specialized medical applications in oncology and preventive care. The company's revenue streams are derived from its core biotechnological services and product sales, with a focus on domestic and overseas markets. Public gene sequencing services cater to broader health screening needs, while clinical sequencing services address specific medical conditions, particularly cancer-related genetic screening. The firm's biochemical instruments and reagents support laboratory operations in both research and clinical settings, serving a diverse clientele across multiple healthcare segments. Genomics Bioscience & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomics Bioscience & Technology Co stock

Inventory of Genomics Bioscience & Technology Co is 235.82 M TWD in 2025.

Inventory of Genomics Bioscience & Technology Co changed from 185.49 M TWD to 235.82 M TWD, representing a 27.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Genomics Bioscience & Technology Co since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Genomics Bioscience & Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genomics Bioscience & Technology Co

All Key Metrics — Genomics Bioscience & Technology Co